Chondroitin-4-sulfate (CSA) (CSA)

Chondroitin-4-sulfate (C4S) is a sulfated glycosaminoglycan (GAG) composed of alternating sugars, specifically N-acetylgalactosamine and glucuronic acid, with a sulfate group at the C4 position [1]. It is a primary constituent of the extracellular matrix in connective tissues, most notably cartilage, where it provides structural integrity and resistance to compressive forces [2]. C4S plays a multifaceted role in biology, influencing cell signaling, adhesion, and the regulation of axonal growth in the nervous system [3]. In clinical contexts, it is a major target for osteoarthritis therapy, where exogenous supplementation aims to reduce inflammation and slow cartilage degradation [4]. Furthermore, C4S acts as a specific receptor for the VAR2CSA protein of Plasmodium falciparum, making it a central target for vaccines against placental malaria [5]. Its presence in the glial scar also makes it a target for enzymatic degradation to promote recovery after spinal cord injury [6]. Additionally, alterations in C4S sulfation patterns are observed in various cancers, where it can promote tumor cell migration and metastasis [7]. The molecule is also investigated for its role in atherosclerosis, as it interacts with lipoproteins in the arterial wall [8].

Other names

Chondroitin sulfate AC4SChondroitin sulfate 44-O-sulfogalactosaminoglycanChondroitin 4-sulfate

Chondroitin-4-sulfate acts as a structural precursor for the synthesis of the cartilage extracellular matrix and inhibits pro-inflammatory mediators like interleukin-1 beta and NF-kappaB [4]. In the context of infectious disease, it serves as a specific adhesion receptor for the Plasmodium falciparum protein VAR2CSA, facilitating parasite sequestration in the placenta [5]. Additionally, it acts as an inhibitory molecule in the glial scar, where it binds to receptors like PTPsigma to prevent axonal regeneration [6].